Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04MBS
|
|||
| Former ID |
DIB005355
|
|||
| Drug Name |
BMS-182657
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Terminated | [1] | |
| Company |
Bristol-Myers Squibb Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H22N2O4S
|
|||
| Canonical SMILES |
C1CC2=CC=CC=C2N(C(=O)C1NC(=O)C(CC3=CC=CC=C3)S)CC(=O)O
|
|||
| InChI |
1S/C21H22N2O4S/c24-19(25)13-23-17-9-5-4-8-15(17)10-11-16(21(23)27)22-20(26)18(28)12-14-6-2-1-3-7-14/h1-9,16,18,28H,10-13H2,(H,22,26)(H,24,25)/t16-,18-/m0/s1
|
|||
| InChIKey |
TYXFDFMUHPWCDX-WMZOPIPTSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensin-converting enzyme (ACE) | Target Info | Modulator | [1] |
| Neutral endopeptidase (MME) | Target Info | Modulator | [1] | |
| KEGG Pathway | Renin-angiotensin system | |||
| Hematopoietic cell lineage | ||||
| Protein digestion and absorption | ||||
| Alzheimer's disease | ||||
| Chagas disease (American trypanosomiasis) | ||||
| Hypertrophic cardiomyopathy (HCM) | ||||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Angiotensin Metabolism | |||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | Metabolism of Angiotensinogen to Angiotensins | |||
| Primary Focal Segmental Glomerulosclerosis FSGS | ||||
| Alzheimers Disease | ||||
| ACE Inhibitor Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 1995 Nov;275(2):745-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.